600873 梅花生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入6,486,560-6.67%27,760,61227,937,15323,060,95617,049,514
减:营业总成本5,754,967-4.61%24,158,62322,990,08120,420,44715,908,470
    其中:营业成本5,232,610-6.07%22,297,12220,915,78418,585,71314,548,203
               财务费用(34,764)-286.89%(33,427)83,877176,935140,944
               资产减值损失----(5,415)(5,958)(20,500)(12,310)
公允价值变动收益260-112.40%(38,116)32,687(22,024)(82,213)
投资收益3,912124.56%7,62724,365307,90635,723
    其中:对联营企业和合营企业的投资收益(593)-301.81%1,8463,074(354)5,633
营业利润885,853-6.27%3,813,3935,160,1792,929,4321,186,031
利润总额875,531-6.64%3,723,1365,152,7952,883,4121,178,298
减:所得税费用123,827-9.65%542,186746,553456,108172,865
净利润751,705-6.13%3,180,9504,406,2422,427,3041,005,432
减:非控股权益--------25,05623,369
股东净利润751,705-6.13%3,180,9504,406,2422,402,248982,064

市场价值指针
每股收益 (元) *0.2600.00%1.0601.4400.7800.320
每股派息 (元) *----0.4170.4000.4000.300
每股净资产 (元) *5.05018.86%4.8124.4423.4282.931
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容